{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:44:47Z","timestamp":1761871487494,"version":"build-2065373602"},"reference-count":24,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T00:00:00Z","timestamp":1642464000000},"content-version":"am","delay-in-days":382,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.clml.2020.08.014","type":"journal-article","created":{"date-parts":[[2020,8,24]],"date-time":"2020-08-24T11:46:32Z","timestamp":1598269592000},"page":"e32-e38","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Effectiveness and Safety of Subcutaneous Rituximab for Patients With Gastric MALT Lymphoma: A Case\u2013Control Comparison With Intravenous Rituximab"],"prefix":"10.1016","volume":"21","author":[{"given":"Hugo","family":"Rotkopf","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Micha\u00ebl","family":"L\u00e9vy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christiane","family":"Copie-Bergman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jehan","family":"Dupuis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muriel","family":"Verlinde-Carvalho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1578-4058","authenticated-orcid":false,"given":"Emmanuel","family":"Itti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlotte","family":"Gagniere","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karim","family":"Belhadj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6439-1782","authenticated-orcid":false,"given":"Jenny","family":"Tannoury","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabien","family":"Le Bras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iradj","family":"Sobhani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corinne","family":"Haioun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6676-1222","authenticated-orcid":false,"given":"Aurelien","family":"Amiot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2020.08.014_bib1","doi-asserted-by":"crossref","first-page":"319","DOI":"10.4103\/1319-3767.141696","article-title":"Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) in ulcerative colitis","volume":"20","author":"Terada","year":"2014","journal-title":"Saudi J Gastroenterol"},{"key":"10.1016\/j.clml.2020.08.014_bib2","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1182\/asheducation-2005.1.307","article-title":"Clinical presentation and management of marginal zone lymphomas","author":"Thieblemont","year":"2005","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"10.1016\/j.clml.2020.08.014_bib3","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1136\/gutjnl-2011-300495","article-title":"Long-term clinical outcome of gastric MALT lymphoma after eradication of Helicobacter pylori: a multicentre cohort follow-up study of 420 patients in Japan","volume":"61","author":"Nakamura","year":"2012","journal-title":"Gut"},{"issue":"suppl 6","key":"10.1016\/j.clml.2020.08.014_bib4","doi-asserted-by":"crossref","first-page":"vi144","DOI":"10.1093\/annonc\/mdt343","article-title":"Gastric marginal zone lymphoma of MALT type: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"24","author":"Zucca","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2020.08.014_bib5","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1200\/JCO.2016.70.6994","article-title":"Final results of the IELSG-19 randomized trial of mucosa-associated lymphoid tissue lymphoma: improved event-free and progression-free survival with rituximab plus chlorambucil versus either chlorambucil or rituximab monotherapy","volume":"35","author":"Zucca","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.08.014_bib6","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/apt.12635","article-title":"Rituximab, alkylating agents or combination therapy for gastric mucosa\u2013associated lymphoid tissue lymphoma: a monocentric non-randomised observational study","volume":"39","author":"Amiot","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.clml.2020.08.014_bib7","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1182\/blood-2002-11-3502","article-title":"Variable frequencies of t(11;18)(q21;q21) in MALT lymphomas of different sites: significant association with CagA strains of H.\u00a0pylori in gastric MALT lymphoma","volume":"102","author":"Ye","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.08.014_bib8","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1053\/gast.2002.33047","article-title":"t(11;18) is a marker for all stage gastric MALT lymphomas that will not respond to H.\u00a0pylori eradication","volume":"122","author":"Liu","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clml.2020.08.014_bib9","doi-asserted-by":"crossref","first-page":"e272","DOI":"10.1016\/S2352-3026(17)30078-9","article-title":"Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial","volume":"4","author":"Davies","year":"2017","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2020.08.014_bib10","doi-asserted-by":"crossref","first-page":"e128","DOI":"10.1016\/S2352-3026(16)00004-1","article-title":"Pharmacokinetics, safety, and efficacy\u00a0of subcutaneous versus intravenous rituximab plus chemotherapy as treatment for chronic lymphocytic leukaemia (SAWYER): a phase 1b, open-label, randomised controlled non-inferiority trial","volume":"3","author":"Assouline","year":"2016","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2020.08.014_bib11","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1111\/bjh.16227","article-title":"Safety of switching from intravenous to subcutaneous rituximab during first-line treatment of patients with non-Hodgkin lymphoma: the Spanish population of the MabRella study","volume":"188","author":"Garc\u00eda-Mu\u00f1oz","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2020.08.014_bib12","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1007\/s12325-017-0610-z","article-title":"Subcutaneous rituximab for the treatment of B-cell hematologic malignancies: a review of the scientific rationale and clinical development","volume":"34","author":"Davies","year":"2017","journal-title":"Adv Ther"},{"issue":"suppl 1","key":"10.1016\/j.clml.2020.08.014_bib13","first-page":"1506","article-title":"IELSG-38: a phase II study of chlorambucil in combination with rituximab followed by maintenance therapy with subcutaneous rituximab in patients with extranodal marginal zone B-cell lymphoma of mucosa associated lymphoid tissue (MALT)","volume":"130","author":"Stathis","year":"2017","journal-title":"Blood"},{"author":"Swerdlow","key":"10.1016\/j.clml.2020.08.014_bib14"},{"key":"10.1016\/j.clml.2020.08.014_bib15","first-page":"218","article-title":"[Clinical staging classification of non-Hodgkin\u2019s lymphomas]","volume":"153","author":"Musshoff","year":"1977","journal-title":"Strahlentherapie"},{"key":"10.1016\/j.clml.2020.08.014_bib16","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/S0016-5107(97)70120-2","article-title":"Endoscopic ultrasonography for the initial staging and follow-up in patients with low-grade gastric lymphoma of mucosa-associated lymphoid tissue treated medically","volume":"46","author":"L\u00e9vy","year":"1997","journal-title":"Gastrointest Endosc"},{"key":"10.1016\/j.clml.2020.08.014_bib17","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1002\/1097-0142(19831015)52:8<1410::AID-CNCR2820520813>3.0.CO;2-3","article-title":"Malignant lymphoma of mucosa-associated lymphoid tissue. A distinctive type of B-cell lymphoma","volume":"52","author":"Isaacson","year":"1983","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2020.08.014_bib18","doi-asserted-by":"crossref","first-page":"284","DOI":"10.3109\/10428190903431820","article-title":"Treatment of t(11;18)-positive gastric mucosa-associated lymphoid tissue lymphoma with rituximab and chlorambucil: clinical, histological, and molecular follow-up","volume":"51","author":"L\u00e9vy","year":"2010","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2020.08.014_bib19","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1182\/blood-2002-11-3496","article-title":"Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type","volume":"102","author":"Conconi","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.08.014_bib20","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1200\/JCO.2005.08.128","article-title":"Clinical activity of rituximab in gastric marginal zone non-Hodgkin\u2019s lymphoma resistant to or not eligible for anti\u2013Helicobacter pylori therapy","volume":"23","author":"Martinelli","year":"2005","journal-title":"J\u00a0Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.clml.2020.08.014_bib21","doi-asserted-by":"crossref","first-page":"940","DOI":"10.3109\/10428194.2012.729832","article-title":"Rituximab and chlorambucil versus rituximab alone in gastric mucosa-associated lymphoid tissue lymphoma according to t(11;18) status: a monocentric non-randomized observational study","volume":"54","author":"L\u00e9vy","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2020.08.014_bib22","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1136\/gut.52.11.1656","article-title":"Proposal for a new histological grading system for post-treatment evaluation of gastric MALT lymphoma","volume":"52","author":"Copie-Bergman","year":"2003","journal-title":"Gut"},{"key":"10.1016\/j.clml.2020.08.014_bib24","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.3324\/haematol.2017.173583","article-title":"Efficacy and safety of subcutaneous and intravenous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line diffuse large B-cell lymphoma: the randomized MabEase study","volume":"102","author":"Lugtenburg","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2020.08.014_bib25","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1080\/1744666X.2019.1562905","article-title":"Infusion-related reactions to rituximab: frequency, mechanisms and predictors","volume":"15","author":"Paul","year":"2019","journal-title":"Expert Rev Clin Immunol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265020304328?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265020304328?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:35:23Z","timestamp":1761870923000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265020304328"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["S2152265020304328"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2020.08.014","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effectiveness and Safety of Subcutaneous Rituximab for Patients With Gastric MALT Lymphoma: A Case\u2013Control Comparison With Intravenous Rituximab","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2020.08.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}